West Pharmaceutical Services (WST) Accumulated Expenses (2009 - 2026)

West Pharmaceutical Services has disclosed Accumulated Expenses across 18 years of filings, most recently posting $46.6 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $46.6 million, down 31.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $46.6 million (down 31.27% YoY), and the FY2025 annual result was $39.2 million, down 46.67% from the prior year.
• Accumulated Expenses came in at $46.6 million for Q1 2026 at West Pharmaceutical Services, up from $39.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $111.8 million in Q3 2025 to a low of $39.2 million in Q4 2025.
• The 5-year median for Accumulated Expenses is $78.1 million (2022), against an average of $77.6 million.
• Peak annual rise in Accumulated Expenses reached 40.45% in 2025, while the deepest fall reached 46.67% in 2025.
• West Pharmaceutical Services' Accumulated Expenses stood at $76.8 million in 2022, then jumped by 37.89% to $105.9 million in 2023, then sank by 30.59% to $73.5 million in 2024, then tumbled by 46.67% to $39.2 million in 2025, then advanced by 18.88% to $46.6 million in 2026.
• The last three Accumulated Expenses figures came in at $46.6 million (Q1 2026), $39.2 million (Q4 2025), and $111.8 million (Q3 2025), per Business Quant data.